InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.70
(
-0.11%
)
Bitcoin
64,877.00
(
-0.40%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

ghmm

Send PM Follow Ignore
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

ghmm

Re: DewDiligence post# 215180

Wednesday, 11/15/2017 7:29:11 PM

Wednesday, November 15, 2017 7:29:11 PM

Post# of 252255
NKTR:

Yes they said they started enrolling (the sarcoma study) a few weeks ago.

They'll actually have (at least) 4 separate trials with 214 combo reporting data in '18
. PIVOT-02 (combo with Nivo)
. The Sarcoma study (combo with Nivo)
. PROPEL (combo Tecentriq or Keytruda)
. REVEAL (combo with NKTR-262)

The takeda program has some programs with approved agents so something may enter clinic in '18

THere was also a preclinical poster with a cancer vaccine (jbog posted an article)

Also they are looking at combo with other agents
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up